Peptide Therapy Near Me: Find a Clinic and Check It First

By Peptide Care Index · Sources checked October 15, 2026

For peptide therapy near me, start with a local medical practice or telehealth clinician authorized to treat you where you are, and book an evaluation before buying treatment. Then check the exact product: approved drugs like Wegovy fill through pharmacies, while BPC-157 and the TB-500 fragment have no FDA-approved product.

A nearby address tells you where a business is. It doesn't tell you who will treat you, which pharmacy makes the product, or what the full bill will be. Below you'll find how to build a short list, a two-stage checklist with official lookups, what three real clinic pages do and don't tell you, and the questions to send before you book. This is a guide to finding and checking care, not a live nearby-clinic directory.

Where to start, depending on what you want:

• An FDA-approved peptide drug, like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro)? Start with your own doctor or another clinician authorized to prescribe for your condition. Ask a pharmacy about the exact brand and your plan about coverage.
• BPC-157, TB-500, or another peptide with no FDA-approved product? A clinic advertisement is not proof of a lawful supply route. For BPC-157 and the TB-500 fragment, the records below do not establish a routine compounding route; FDA's Category 1 interim policy does not cover an ingredient simply because its nomination was withdrawn. Use the checklist before you pay.
• Sermorelin or another growth-hormone peptide? Compounded offers exist. Ask which pharmacy makes it and what legal basis that pharmacy relies on.
• Not sure which peptide, or whether you need one? Book a medical evaluation, not a package. You don't have to pick a peptide first.
• No clinic nearby that you trust? A telehealth clinician must be licensed or otherwise permitted where you are during the visit. The same checks apply.

How to find peptide therapy near me without guessing

Start with the kind of visit you need, then find practices that actually provide it. A map listing gives you names and addresses; the practice still has to confirm who will see you, where, and for what fee.

Here's where to look, based on where you're starting. These are search paths, not treatment recommendations.

Build a short list, then check each one

Use your own map or directory search with your city or ZIP code. Simple searches work well:

• peptide therapy [your city]
• peptide clinic [your city]
• [medicine name] consultation [your city], if you already have a named medicine to discuss

These are search ideas, not a guarantee of what you'll find. Pick two or three candidates based on travel time and appointment availability. Then ask each one a simple question: "Is this address where the medical appointment happens, where I'd pick up a product, or just your business address?"

That question matters. One clinic directory says it rejects telehealth brands that list a fake local address to show up in "near me" searches (HealingMaps listing rules, checked October 15, 2026). If a "local" clinic's only real office is in another state, treat it as telehealth and check licensing for where you are.

Peptide clinic directories can help you build a list. They usually show addresses, services, and peptide menus. What they generally don't do is tell you whether a clinic can lawfully supply a specific peptide, or what the full bill will be. That's what the checklist below is for.

If you're looking at research studies, read the full record. For example, one U.S. BPC-157 study after rotator-cuff surgery, sponsored by the University of Arkansas and listing the University of Arkansas for Medical Sciences in Little Rock, was listed as not yet recruiting, with an estimated start of January 1, 2027. Its summary says 20 patients, while its enrollment field says 30, estimated. No results are posted; the record also conflicts over whether the comparison group receives saline injections or no injections (NCT07803250, last update posted September 3, 2026; full record checked October 15, 2026). Only the study team can confirm recruitment and whether you qualify.

You don't have to choose a peptide first

You can book an evaluation to talk about your concern without buying a treatment in advance. Ask whether the clinician will discuss established options, including no new medication, before offering a prepaid package.

It helps to know that four different jobs can be handled by four different people or businesses:

• Consultation: a clinician evaluates you.
• Prescribing: a licensed prescriber writes an order for a specific medicine.
• Dispensing: a pharmacy prepares or supplies it.
• Administration: someone gives the medicine; teaching you how to use it is a separate service to confirm.

A clinic, a clinician, a pharmacy, and a medicine can all be separate. Knowing which is which makes every other question easier to ask.

Local peptide clinic checklist: what to confirm before you pay

Check the appointment before you pay for a consultation. Check the exact offer before you pay for treatment. Some product details won't exist until after an evaluation, and that's normal; it's different from being asked to buy a product whose identity or source is unclear.

Local peptide clinic checklist. Framework checked October 15, 2026. A decision aid, not a clinic accreditation or a medical assessment.

Use the regulator that matches the clinician's credential. A registered nurse license isn't prescribing authority, and nurse practitioner and physician assistant rules vary by state, so check the license itself rather than a clinic badge.

What three clinic pages tell you, and what they leave open

A clinic's page can answer useful questions without answering all of them. These three examples show what each reviewed service page published on October 15, 2026. They're listed alphabetically, chosen because they appeared in search results and disclose different things. We don't rank, rate, or endorse them, and a gap on the page doesn't mean the clinic can't answer the question.

Three clinic service pages, compared. Checked October 15, 2026. Provider-published statements only.

Here's the practical meaning. Free, $75, and evaluation-first describe different appointment offers, not treatment prices. LIVation's free invitation and paid FAQ also need an explanation before you choose an appointment. The clinic that says least about price on its page may still give you the clearest written offer, so ask.

A worked example: checking one fee claim

We use a simple method for every claim, called the Peptide Care Access Check. It names the decision, the evidence, what we checked, the finding, the next question, and what would change our answer. Here it is applied to LIVation's consultation fee.

Our findings are always one of five labels: Supported, Contradicted, Unresolved, Conflicting, or Not applicable. They describe one specific claim, never a whole clinic. There's no "verified clinic" badge here, on purpose.

Found a clinic, but still missing the pharmacy name, the fee details, or a clear description of what you'd be buying? Peptide Care Index's Find My Peptide Path tool walks you through the provider, fee, and access questions to settle before you pay, and lets you copy or print them. Its provider and fee checks work for any clinic, even if your peptide doesn't have its own access summary. Free to use, with no account or email.

Find My Peptide Path

Clinic claims vs. what the records show

Some clinic claims sound like proof but answer a different question. A license proves something about a person. A pharmacy license proves something about a pharmacy. Neither, alone, proves that a specific peptide can be supplied to you.

Here's what common claims do and don't establish. The first rows come from a real Chicago med spa page that offers BPC-157; we show it to explain how to read a claim, not to judge that clinic.

Common clinic claims, compared with the records. Checked October 15, 2026; historical source dates are identified in the linked records.

A clinic can be honest, licensed, and well-meaning and still be relying on a legal basis that the public records don't confirm. That's why the product question gets its own check.

Local clinic or telehealth: which fits the visit you need?

Neither is automatically safer. A local address doesn't prove a clinic can supply a particular peptide, and a telehealth clinician must be licensed or permitted where you are, just like a local one. What really differs is whether you get an in-person exam, labs on site, and hands-on teaching.

Compare what happens during the visit, not just how it's booked. An in-person practice, a remote prescriber, and a local lab can be separate parts of one arrangement.

Your physical location matters for remote care

Tell the practice where you'll actually be during the appointment, especially if you travel. HHS lists several ways a clinician may practice across state lines: a full license, temporary-practice laws, reciprocity, a licensure compact, or telehealth registration where available (HHS, updated April 30, 2025). The rules depend on the state, so ask how the clinician is permitted to treat you there.

Where each fits best:

• In person fits when you want a physical exam, labs drawn in the same place, or someone to teach you face to face.
• Telehealth fits when nothing local passes the checklist, you want to compare more offers, or travel is hard.
• Either needs the same checklist. If you only need directions to a clinic you've already chosen, use that clinic's own location page.

Want to compare online offers too? See our comparison of three published online peptide care offers, listed alphabetically with the details to resolve before paying.

What a clinic near you can offer depends on the exact peptide

"Peptide therapy" isn't one medicine or one approval category. A clinician can discuss approved peptide medicines within their scope of practice, but an advertised peptide menu is not an approval record. When the offer is compounded, check the exact source and access basis. For BPC-157 and the TB-500 fragment, the BPC-157 and TB-500 ingredient records, current bulks list, and Category 1 policy do not establish a routine section 503A compounding route.

Four terms that change the answer

• FDA-approved: a finished drug FDA reviewed for specific uses, such as Wegovy.
• Compounded: prepared by combining, mixing, or altering ingredients to make a medicine. Compounding can be performed by an authorized pharmacist or physician; a 503B outsourcing facility can supply certain office-use drugs without patient-specific prescriptions. Compounded drugs are not FDA-approved, and FDA doesn't review them for safety, effectiveness, or quality before they're sold (FDA).
• 503A pharmacy: a pharmacy using the patient-specific compounding pathway; section 503A also covers qualifying physician compounding. To qualify for its exemptions, a bulk ingredient must comply with an applicable USP/NF monograph if one exists; if none exists, it must be a component of an FDA-approved drug or appear on FDA's 503A bulks list. Other conditions still apply (FDA). A 503B outsourcing facility is an FDA-registered facility engaged in sterile drug compounding under a licensed pharmacist's supervision—not simply a larger pharmacy (FDA).
• FDA's interim categories: lists for ingredients nominated for the 503A list while FDA reviews them. Category 1 ingredients may be eligible and had enough information for FDA to evaluate. Category 2 ingredients may be eligible, but FDA has identified significant safety risks and does not extend its Category 1 policy to them. Category 3 ingredients were nominated without enough information to evaluate (FDA). None of these categories is an approval or the final list. FDA's interim policy is conditional enforcement discretion for Category 1, not product approval.

Status of peptides clinics commonly advertise

These are peptides that clinic directories and clinic pages list on their menus. The table shows what the federal records say about each one, not whether it works or suits you.

Status of commonly advertised peptides. Records checked October 15, 2026; the 503A inventory is dated May 14, 2026, and the 503B inventory March 21, 2025. A withdrawn nomination is not a move into Category 1. The interim policy expressly requires Category 1 listing and other conditions. A category record is not a product-approval record or a ruling on a particular pharmacy. Where no approved product is established below, ask for an exact FDA application rather than treating an advertisement as proof.

Sources for the compounding columns: FDA's 503A category list, 503B category list, and safety-risk page, plus 21 CFR 216.23. For every record, route, and download, see our FDA peptide compounding list and status table. For named approved products, see our FDA-approved peptides list.

Two things are easy to miss in this table. First, the approved drugs at the top can be discussed through ordinary medical care: an appropriately authorized prescriber can evaluate them, and a pharmacy can explain its filling arrangements and availability. Second, "a clinic offers it" and "the records support supplying it" are different claims. A clinic advertisement is evidence of an advertised service, nothing more.

TB-500 needs extra care. FDA's briefing describes TB-500 as an N-acetylated seven-amino-acid fragment of thymosin beta-4 (LKKTETQ, residues 17–23), which is a different substance from the full 43-amino-acid peptide (briefing, p. 25). Research on the full protein doesn't automatically apply to the fragment. Our TB-500 human evidence review keeps the two apart.

What did FDA's 2026 meeting decide?

FDA's compounding advisory committee met July 23–24, 2026, and discussed BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon (FDA meeting page). Advisory committees make recommendations FDA doesn't have to follow, so the meeting itself isn't an approval or a listing decision. FDA has announced a follow-up meeting before the end of February 2027; that announcement is not a final ingredient-list action. We track dates, agendas, and records in what the FDA peptide meetings did and didn't decide.

What reviews, licenses, and purity claims can't settle

A good review describes one person's experience. A license record answers a question about a professional. A certificate of analysis answers a question about one tested sample. None of them, alone, proves that a specific product works for your purpose or can lawfully be supplied to you.

A product labeled "for research use" isn't a patient treatment, whatever a seller says. If you're looking specifically at BPC-157, our guide to BPC-157 access routes and provider checks and our BPC-157 FDA approval and compounding status page go deeper.

What will peptide therapy near me really cost?

There's no single price for "peptide therapy." The price depends on the exact product, how much of it you get, which services come with it, and how you're billed. Compare like with like, and keep the consultation separate from any later treatment commitment.

Published prices show how differently clinics charge. These rows are examples, not a market average, and they aren't added together or ranked.

Published price examples. Not ranked. Conditions stay beside each price.

For more listed prices with package sizes, see our dated peptide price list and BPC-157 cost and published fees.

What every written quote should state

Ask for a quote that fills in each line below. Write "not stated" or "not yet known" where the clinic hasn't answered. Never fill a blank with $0.

Hypothetical: how a $99-a-month headline becomes $597

This example uses made-up numbers. It isn't any provider's price or a recommended course of treatment. Our calculation: the stated charges add to $597.

Say an offer advertises "$99 a month" and its fine print requires all of this upfront:

The first payment is $597, not $99. Even that isn't the whole cost if repeat visits, renewal, or later testing aren't priced yet. And the three-month billing term says nothing about how long anyone should use a medicine.

Insurance and self-pay estimates

Ask the practice and your insurer about each part separately: the evaluation, the tests, and the exact medicine. "We accept insurance" doesn't mean the whole offer is covered. Health plans may cover some FDA-approved peptide drugs for their labeled uses, depending on your plan, and you shouldn't assume coverage for compounded products until your plan confirms it in writing.

If you aren't using insurance, you usually have the right to a good faith estimate of expected charges when you ask for one, or when you schedule at least three business days ahead. Each provider or facility gives its own estimate, so a clinic and a separate lab may each give one (CMS, updated October 5, 2026).

Got a quote with blanks in it? The fee section of Peptide Care Index's Find My Peptide Path tool lists each charge to ask about, including any missing from your quote, so you can see what's missing before you agree to anything.

Find My Peptide Path

What should happen at the first visit, and afterward?

Use the first medical visit to understand the proposed treatment and its alternatives, not to pick a package. Before you start anything, you should know who explained the evidence, who reviewed the risks for you, and who handles follow-up.

Bring your goal in one sentence, a list of your current medicines and supplements, and any recent lab results. Then ask four questions:

1. What problem are we evaluating? The answer should be about you, not about a product.
2. What supports this exact medicine and route for my situation? For an approved drug, that's its label and evidence. For a peptide with no approved product, ask what human evidence exists. Our reviews of BPC-157 human studies and TB-500 human evidence show how limited that evidence is for those two.
3. What are the established alternatives, including no new medication?
4. What follow-up do you recommend, and what does it cost?

Do not assume one "peptide lab panel" or testing schedule fits every medicine or patient. Ask the practice to say which tests it requires for this specific service and why. A completed blood test, on its own, doesn't show that a product with no FDA approval is appropriate.

Safety basics

For FDA-approved peptide drugs, the label lists known side effects and who shouldn't use them, so ask your clinician to go over them for the exact product. For BPC-157 and the TB-500 fragment, FDA describes possible immune reactions with certain routes and concerns about peptide-related impurities, and reports little or no human safety information (FDA safety-risk page). That means the risks are less known, not proven low. Our peptide side effects chart collects what's documented by peptide.

Tell every clinician you see what you're taking. If you have signs of a severe allergic reaction after any injection, like trouble breathing or swelling of the face or throat, get emergency care right away (MedlinePlus: anaphylaxis).

What "injections" and "support included" should mean

Ask whether the service includes giving the injection at the clinic, teaching from a clinician, or only prescribing and follow-up. Ask who answers medical questions after the appointment, how to reach them, during which hours, and whether there's a promised response time or extra charge. A general customer-service inbox isn't a clinical support plan.

Also ask what happens if the prescriber leaves or the pharmacy stops supplying the product. Share your medical history directly with the clinician through the practice's secure channel, not through a public form.

Questions you can send before booking

Ask about the appointment first. Save the product questions for when a treatment is actually proposed, and get those answers before you commit to it.

Before I book

I'm comparing options for a medical evaluation. Please confirm the appointment location or remote format, the name and credential of the clinician who will see me, and that they can treat me where I'll be during the appointment.

Is this a medical consultation or an introductory sales call? What is the fee, what does it include, and what is your cancellation policy? What do I pay if the clinician doesn't prescribe anything?

Before I pay for a proposed treatment

Please give me the exact medicine and its form, how it's given, the quantity supplied, and the name of the pharmacy that dispenses it. Please explain the legal basis for supplying this specific product. A general statement that the clinic or pharmacy is licensed doesn't answer that question.

Please itemize the medicine, required labs, visits, membership, shipping, supplies, and follow-up. What is due now, what is the minimum commitment, and what renews automatically?

What happens to my payment if no prescription is written or the pharmacy can't fill it? Who handles medical questions and changes in treatment or supply?

My notes (keep these private)

• Clinic and date: ______
• Appointment format and consultation cost: ______
• Treating clinician, and where I checked the license: ______
• Proposed medicine and pharmacy, once known: ______
• Amount due at the start, and renewal terms: ______
• Questions still open: ______

Source: Peptide Care Index, local peptide clinic checklist, checked October 15, 2026. Article and checklist. Official references: HHS telehealth licensure · state medical boards · Nursys QuickConfirm · state nursing boards · boards of pharmacy · FDA on compounded drugs · CMS good faith estimates

Book the evaluation, ask another question, or pause?

A missing product detail before an evaluation isn't automatically a reason to skip the appointment. An unexplained product or an unclear payment commitment is a reason to pause that purchase.

Red flags that should end the conversation

Walk away if a clinic refuses to identify who will provide the medical evaluation, or asks you to buy a proposed treatment while refusing to name its source. A product sold for research use is not a substitute for clinical care. A lower price can't fix any of those.

• A product is sold to you for treatment under a "research use only" or "not for human consumption" label, or a prescription medicine is sold without a valid prescription.
• No one can tell you who will prescribe, or the prescriber isn't licensed or permitted where you are.
• Before taking payment for a proposed treatment, the clinic won't name the dispensing pharmacy or other supplying facility.
• A compounded product is described as "FDA-approved."
• You're pushed to prepay several months before any evaluation.
• A treatment is offered without a medical-history and risk review, or questions about required testing are brushed aside.
• No one can say what happens to your money if nothing is prescribed.
• A visit advertised as in person turns out to use only a mailing address.

For enforcement records, see our list of FDA warning letters to peptide sellers and our peptide recall records.

What we actually checked

We reviewed public clinic pages and official records to separate what clinics advertise from the questions that still need answers. We didn't book appointments, contact clinics, inspect pharmacies, check any individual's license, buy products, or assess anyone's medical needs.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we actually checked

• Clinic service pages: LIVation, myEvergreen MedSpa, Simply Health Integrated Medical, and Better Med Spa, read October 15, 2026. AgelessRx offer and FAQ, read October 15, 2026. These show what each provider publishes, not confirmed fulfillment or what patients actually paid. We did not complete an intake or obtain a personalized checkout quote.
• FDA records: the cited Drugs@FDA product records; the discontinued Geref record and FDA's March 4, 2013 determination; BPC-157 and TB-500 staff briefing passages, including the fragment identity; the current 503A/503B category inventories, safety-risk page, January 2025 interim guidance, and 21 CFR 216.23; the July 2026 meeting page and follow-up announcement. Checked October 15, 2026. Source publication dates remain attached to their findings.
• Licensing and billing guidance: HHS telehealth licensure pages, official license and pharmacy-board directories, and CMS good faith estimate guidance, checked October 15, 2026.
• Prices and registry: provider and manufacturer offer/terms pages, and the complete NCT07803250 registry record, checked October 15, 2026. The registry is a sponsor-submitted record, not confirmation of recruitment. We also read the October 14 edition of our 18-letter register and the cited FDA Gram Peptides letter; this was not a new audit of every letter in that register.
• How we chose examples: they appeared in U.S. search results for this topic and show different kinds of disclosure. This isn't a list of the best or nearest clinics.
• Limits: This is editorial source review. It hasn't been reviewed by a clinician, pharmacist, or regulatory specialist. We don't rate clinics or recommend a peptide or dose.

Read how we compare, our editorial standards, who publishes this site, and how we make money. AI tools assisted with drafting, editing, and source retrieval, as described in our editorial standards.

Common questions

Can I get peptides at a regular pharmacy near me?

Yes, an FDA-approved peptide medicine can be filled through a pharmacy with a valid prescription, although stock, insurance, and dispensing arrangements differ by product. The approved-product records above identify Wegovy, Ozempic, Mounjaro, and Vyleesi. BPC-157 and the TB-500 fragment have no approved finished product; a local advertisement or compounding claim does not establish a routine supply route. A withdrawn nomination alone does not meet FDA's Category 1 interim-policy condition.

Can a nurse practitioner or physician assistant prescribe peptides?

It depends on your state's rules for that profession and on the product. Check the person's license with the matching regulator (Nursys QuickConfirm or the state nursing board for nurse practitioners; DocInfo or the relevant state regulator for physician assistants). Then ask the product question separately, because prescribing authority doesn't settle whether a product can be supplied.

Can I buy peptides near me without a prescription?

The prescription medicines discussed here require a valid prescription. A research-use label does not turn a store purchase into medical care: FDA's Gram Peptides letter explains why such disclaimers did not override the seller's human-use marketing. Our warning-letter register keeps those records separate from legitimate medical prescribing. For treatment, start with a licensed clinician.

Is there a BPC-157 clinic near me?

Some local clinics advertise BPC-157, but no FDA-approved BPC-157 product exists, and the records we checked don't confirm a basis for compounding it. If you're considering it, read BPC-157 access routes and provider checks before you book, and use the checklist on this page for any clinic you find.

Your next step: choose the visit, not a promise

You can choose a medical evaluation without agreeing to a treatment package. Start with a clearly defined appointment. When there's an actual offer, check the exact medicine, the pharmacy, the follow-up, and the full payment commitment before you pay.

Use Find My Peptide Path to keep the remaining questions in one place: the dated access record for BPC-157, TB-500, or sermorelin if that's what you're considering, plus provider and fee checks and questions you can copy for any clinic, including one you already trust. It won't choose a clinic or a medicine for you. It's free, with no account or email.

Find My Peptide Path

Sources and check dates

Clinic and manufacturer pages show what each business publishes. FDA briefing documents are staff analysis prepared for an advisory meeting, not final agency decisions.

1. U.S. Department of Health and Human Services. Getting started with licensure. Licensure where the patient is located. Last updated February 21, 2024. Checked October 15, 2026.
2. U.S. Department of Health and Human Services. Licensing across state lines. Cross-state practice options. Last updated April 30, 2025. Checked October 15, 2026.
3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A. Ingredient conditions, category definitions, and other applicable requirements. Checked October 15, 2026.
4. Electronic Code of Federal Regulations. 21 CFR 216.23. The 503A bulks list; Title 21 displayed current through October 13, 2026. Checked October 15, 2026. The displayed currency date is not the date a peptide rule changed.
5. U.S. Food and Drug Administration. BPC-157 briefing, July 2026 advisory meeting. Approval and monograph statement on printed page 9; that page was visually inspected. Staff evaluation dated May 11, 2026. Checked October 15, 2026.
6. U.S. Food and Drug Administration. TB-500 briefing, July 2026 advisory meeting. Printed page 7 for approval/monograph; printed page 25 for the N-acetylated fragment identity. Both pages visually inspected. Staff evaluation dated May 15, 2026. Checked October 15, 2026.
7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current withdrawn-nomination entries, route-specific concerns, and separate Category 2 records. Checked October 15, 2026.
8. U.S. Food and Drug Administration. 503A category inventory, updated May 14, 2026, and 503B category inventory, updated March 21, 2025. Relevant rows visually inspected; checked October 15, 2026. These are category inventories, not approved-product lists.
9. U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting, and announced follow-up before the end of February 2027. Checked October 15, 2026. No vote tally is reported here.
10. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Nonapproval, compounding participants, and 503B facility distinction. Checked October 15, 2026.
11. U.S. Food and Drug Administration. Understanding Unapproved Use of Approved Drugs "Off Label". Checked October 15, 2026.
12. U.S. Food and Drug Administration. Registered Outsourcing Facilities. List updated as of September 30, 2026. Checked October 15, 2026.
13. Drugs@FDA. Wegovy, NDA 215256; Ozempic, NDA 209637; Mounjaro, NDA 215866; Vyleesi, NDA 210557. Product records checked October 15, 2026. Also inspected the relevant opening label pages for Wegovy, June 2026 and Vyleesi's approved HSDD indication; no personal dosing guidance is supplied.
14. Centers for Medicare & Medicaid Services. What is a good faith estimate? Updated October 5, 2026. Checked October 15, 2026; final destination after the supplied URL's redirect.
15. License and board lookups: DocInfo, FSMB state medical boards, Nursys QuickConfirm, NCSBN state nursing boards, NPPES NPI Registry, and NABP boards of pharmacy. Entry pages checked October 15, 2026; no individual license search performed. Nursys leads to terms before lookup. CMS's NPI fact sheet explains why an NPI does not verify licensure.
16. ClinicalTrials.gov. NCT07803250; complete registry record. Last update posted September 3, 2026; checked October 15, 2026. Sponsor, status, dates, location, enrollment fields, comparator descriptions, and absence of posted results were inspected.
17. LIVation. Peptide Therapy. Provider-published. Checked October 15, 2026.
18. myEvergreen MedSpa. Peptide Therapy. Provider-published. Checked October 15, 2026.
19. Simply Health Integrated Medical. Peptide Therapy. Provider-published. Checked October 15, 2026.
20. Better Med Spa and Wellness. BPC-157. Provider-published. Checked October 15, 2026.
21. AgelessRx. Sermorelin Injection and FAQ. Public offer and terms checked October 15, 2026. No personalized checkout or complete upfront quote was obtained.
22. Novo Nordisk. What to pay for Wegovy, retail savings-offer terms, and NovoCare Pharmacy terms. Checked October 15, 2026. The article's offer row expressly uses the retail terms; other channels and product forms have their own terms.
23. HealingMaps. Peptide Therapy Near Me. Directory listing rules. Checked October 15, 2026.
24. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. January 2025 final guidance; printed page 13 (PDF page 16) contains the Category 1 conditions; printed pages 14–15 address nomination changes and withdrawals. Read October 15, 2026.
25. Drugs@FDA. Geref, NDA 020443; FDA, March 4, 2013 determination about discontinued Geref. Read October 15, 2026. Historic approval and non-safety withdrawal do not approve a current compounded product.
26. FDA staff assessments: ipamorelin, 2024, CJC-1295-related substances, 2024, and thymosin alpha-1, 2024. Approval-related passages checked October 15, 2026; historical assessments are not new final agency actions.
27. U.S. Food and Drug Administration. Gram Peptides warning letter, March 31, 2026. Read October 15, 2026. Used for the specific research-disclaimer/intended-use distinction, not a finding about an unrelated clinic.
28. MedlinePlus, U.S. National Library of Medicine. Anaphylaxis. Emergency signs and need for immediate help; checked October 15, 2026.